sever
vaccin
strategi
aim
gener
cellmedi
immun
cmi
microorgan
tumor
epitopebas
vaccin
offer
advantag
knowledg
specif
epitop
frequenc
major
histocompat
complex
mhc
allel
requir
show
use
promiscu
overlap
synthet
peptid
osp
immunogen
gener
peptidespecif
cmi
vaccin
outbr
mice
differ
strain
inbr
mice
cmi
respons
also
recogn
viral
protein
osp
immunogen
also
induc
cmi
ex
vivo
dendrit
celltcel
cocultur
involv
cell
individu
differ
hla
haplotyp
thu
broad
cmi
induc
osp
differ
experiment
set
use
differ
immunogen
without
identifi
either
epitop
mhc
background
vaccine
viral
infect
remain
major
public
health
concern
recent
emerg
new
human
pathogen
includ
sever
acut
respiratori
syndrom
sar
avian
influenza
virus
reinforc
need
develop
rapid
methodolog
identifi
appropri
vaccin
epidem
identif
cancer
antigen
capabl
stimul
cmi
inspir
develop
antitumor
vaccin
consider
progress
made
toward
develop
prevent
therapeut
cancer
vaccin
efficaci
vaccin
base
upon
epitop
tcell
peptid
melanoma
patient
evalu
immun
peptid
adopt
transfer
peptidepuls
dendrit
cell
dc
gener
favor
result
cmi
import
immun
mechan
contain
infect
caus
mani
virus
herp
simplex
viru
hsv
epsteinbarr
viru
ebv
cytomegaloviru
cmv
human
immunodefici
viru
hiv
lymphocyt
gener
function
helper
th
cytotox
lymphocyt
ctl
respect
recogn
viral
antigen
interact
tcell
receptor
tcr
viral
peptid
display
host
major
histocompat
complex
mhc
molecul
unlik
b
cell
react
stimul
intact
antigen
protein
ctl
directli
recogn
antigen
gener
ctl
respons
antigen
need
present
cytoplasm
compart
antigenpres
cell
apc
antigen
degrad
proteasom
aminopeptidas
peptid
subsequ
bind
mhc
class
molecul
purpos
deliv
antigen
cytoplasm
compart
current
candid
aid
vaccin
employ
live
attenu
vector
eg
canari
pox
recombin
modifi
vaccinia
viru
ankara
mva
adenoviru
plasmid
dna
encod
viral
gene
product
strategi
limit
follow
reason
live
vector
vaccin
immun
respons
vector
compon
may
domin
immun
respons
thu
dampen
immunogen
insert
live
vector
may
problemat
immunocompromis
individu
dna
vaccin
alon
although
gener
strong
ctl
respons
mice
less
effect
higher
anim
epitopebas
peptid
vaccin
dna
vector
encod
peptid
base
upon
known
tcell
epitop
also
effect
induc
ctl
respons
mhc
restrict
breadth
respons
may
narrow
may
favor
viral
escap
variant
use
dna
primemva
boost
strategi
singl
epitop
vaccin
test
rhesu
monkey
although
vaccin
strategi
gener
strong
ctl
activ
fail
protect
monkey
siv
challeng
broaden
ctl
respons
multiepitop
vaccin
develop
number
group
one
multictl
epitop
vaccin
intend
dna
primemva
boost
strategi
consist
pool
ctl
epitop
hiv
clade
gag
mous
monkey
immunogen
studi
subsequ
human
clinic
trial
specif
cmi
measur
enzymelink
immunospot
elispot
analysi
induc
design
epitopebas
vaccin
gener
popul
laborintens
process
involv
assess
frequenc
mhc
type
identif
tcell
epitop
bear
mind
number
mhc
allel
within
popul
number
protein
encod
given
viru
would
difficult
identifi
ctl
epitop
mhc
allel
cope
emerg
epidem
caus
new
microorgan
approach
may
impract
present
novel
vaccin
strategi
util
promiscu
osp
gener
antigenspecif
cmi
individu
vaccin
recipi
differ
mhc
background
osp
repres
sequenti
stretch
amino
acid
aa
known
viral
tumor
antigen
fig
given
peptid
within
osp
pool
overlap
neighbor
peptid
sever
aa
histor
osp
use
identifi
ctl
th
epitop
vitro
osp
contain
ctl
th
epitop
peptid
may
bound
directli
mhc
molecul
express
cell
surfac
ingest
process
apc
furthermor
osp
promiscu
fig
schemat
map
overlap
synthet
peptid
osp
first
amino
acid
aa
protein
sequenc
shown
x
repres
one
essenti
aa
individu
peptid
pn
made
aa
length
mer
overlap
neighbor
peptid
aa
contain
multipl
epitop
bind
differ
mhc
allel
osp
vaccin
could
design
rapidli
neither
epitop
mhc
allel
need
identifi
specif
aa
sequenc
viral
protein
need
known
follow
peptid
obtain
aid
research
refer
reagent
program
divis
aid
niaid
nih
osp
hiv
gag
consensu
b
ospgag
conb
consist
group
peptid
aa
length
aa
overlap
sequenti
peptid
span
entir
hiv
consensu
b
gag
sequenc
peptid
pure
osp
hiv
mn
env
ospenv
mn
consist
seri
peptid
compris
hiv
mn
env
region
peptid
aa
length
overlap
sequenti
peptid
peptid
pure
osp
hiv
gag
iiib
ospgag
iiib
consist
seri
peptid
aa
length
overlap
sequenti
peptid
osp
env
ospenv
siv
consist
seri
peptid
aa
length
overlap
sequenti
peptid
peptid
pure
peptid
amqmlketi
envelop
peptid
hiv
clade
c
gpgqafyat
synthes
molecular
biolog
core
facil
danafarb
cancer
institut
dfci
boston
peptid
pure
randomli
bred
outbr
nmri
mice
tacon
farm
ny
immun
subcutan
sc
ospgag
conb
ospenv
mn
g
individu
peptid
l
pb
per
mous
togeth
mlp
tdm
adjuv
system
sigma
st
loui
mo
three
time
interv
control
group
given
adjuv
pb
anoth
week
last
boost
splenocyt
collect
elispot
assay
intracellular
stain
perform
inbr
mice
balbc
b
tacon
farm
ny
immun
ospgag
iiib
g
individu
peptid
l
pb
per
mous
togeth
mlp
tdm
adjuv
system
sigma
st
loui
mo
control
mice
given
adjuv
immun
given
week
three
week
last
immun
mice
sacrif
ctl
thelper
cell
prolifer
assay
anim
experi
approv
anim
care
use
committe
dfci
facil
dfci
accredit
associ
assess
accredit
laboratori
anim
care
intern
aaalac
procedur
compli
us
govern
principl
util
care
use
vertebr
anim
use
test
research
train
guid
care
use
laboratori
anim
provis
anim
welfar
act
applic
law
regul
leukopack
provid
anonym
normal
blood
donor
dfci
blood
bank
boston
mhc
tissuetyp
perform
brigham
women
hospit
boston
dc
isol
differenti
peripher
blood
mononuclear
cell
pbmc
incub
plastic
cellcultur
flask
h
co
c
adher
cell
collect
incub
complet
rpmi
supplement
granulocytemacrophag
coloni
stimul
factor
gmcsf
stem
cell
technolog
vancouv
canada
dc
medium
addit
ml
dc
medium
ad
cultur
day
day
detach
cell
collect
transfer
new
flask
fresh
dc
medium
dc
puls
overnight
ospenv
siv
follow
irradi
grey
rad
use
gener
ctl
ex
vivo
three
stimul
autolog
pbl
weekli
interv
ctl
assay
perform
week
last
stimul
effector
cell
consist
splenic
mononuclear
cell
isol
ospor
adjuvantonli
immun
mice
restimul
ml
vitro
peptid
day
target
cell
cell
balbc
mice
cell
b
mice
target
cell
label
cr
cell
perkinelm
boston
puls
overnight
without
ospgag
iiib
infect
overnight
vaccinia
viru
two
plaqu
form
unit
pfu
target
cell
express
hiv
gag
iiib
nih
aid
research
refer
reagent
program
wildtyp
vaccinia
viru
therion
cambridg
case
restrict
ctl
amqmlketi
known
ctl
epitop
within
hiv
includ
test
ospgag
iiib
could
gener
restrict
ctl
balbc
mice
nonepitop
peptid
hiv
clade
c
env
peptid
gpgqafyat
use
neg
control
effector
target
cell
cocultur
differ
ratio
h
cytolysi
determin
cr
releas
percentag
specif
cr
releas
calcul
experiment
releas
spontan
releas
maximum
releas
spontan
releas
maximum
releas
determin
supernat
cell
lyse
addit
tritonx
spontan
releas
determin
target
cell
incub
without
addit
effector
cell
effector
cell
consist
pbl
stimul
irradi
autolog
dc
puls
without
osp
target
cell
ebvtransform
autolog
b
cell
line
cell
label
cr
cell
perkinelm
boston
puls
overnight
without
ospsiv
env
infect
overnight
vaccinia
viru
two
plaqu
form
unit
pfu
target
cell
express
siv
gagpolenv
wildtyp
vaccinia
viru
therion
effector
target
cell
cocultur
percentag
specif
cr
releas
calcul
mention
mous
ctl
assay
mous
splenocyt
cultur
cellsml
uml
without
osp
cultur
plate
h
four
hour
harvest
cell
treat
golgistop
bd
pharmingen
san
diego
ca
accord
vendor
protocol
splenocyt
stain
phycoerythrin
pe
conjug
monoclon
rat
antimous
antibodi
bd
pharmingen
immunoglobulin
isotyp
control
min
splenocyt
subject
intracellular
cytokin
stain
use
cytofixcytoperm
kit
bd
pharmingen
fitcconjug
antibodi
gml
accord
manufactur
instruct
sampl
acquir
epic
xl
flow
cytomet
beckman
coulter
fullerton
ca
data
analyz
use
expo
softwar
beckman
coulter
elispot
assay
perform
use
elispot
kit
biosourc
intern
camarillo
ca
briefli
splenocyt
restimul
overnight
osp
plate
cell
discard
biotinyl
antiifni
antibodi
ad
h
c
follow
anoth
hour
incub
c
antibiotin
antibodi
label
enzym
color
develop
spot
count
microscop
result
express
cell
splenocyt
isol
cultur
ml
rpmi
plu
fc
plu
antibiot
presenc
either
hiv
gag
iiib
protein
gml
immunodiagnost
inc
woburn
hiv
env
mn
gml
immunodiagnost
inc
ospgag
iiib
gml
ospenv
mn
gml
ova
gml
day
four
hour
harvest
cell
puls
ciwel
hthymidin
cell
harvest
hthymidin
incorpor
assess
use
beckman
fullerton
ca
result
express
stimul
index
si
ie
ratio
cpm
stimul
cell
cpm
cell
grown
medium
first
sought
determin
set
osp
could
gener
cmi
genet
divers
mice
outbr
nmri
mice
gener
outbr
swiss
mice
random
breed
provid
genet
divers
experiment
group
mice
toler
skin
graft
express
mhc
molecul
similar
q
differ
individu
strain
outbr
nmri
mice
immun
ospgag
conb
repres
consensu
sequenc
hiv
clade
b
gag
ospenv
mn
repres
aa
sequenc
hiv
mn
adjuv
phosphat
buffer
salin
pb
splenocyt
isol
immun
mice
restimul
overnight
vitro
two
correspond
osp
pool
elispot
assay
show
number
spotform
unit
sfu
higher
splenocyt
ospgag
conb
ospenv
mn
immun
mice
cell
restimul
correspond
osp
compar
control
gag
versu
env
immun
p
gag
env
restimul
respect
student
ttest
fig
b
sfu
individu
mice
two
vaccin
group
rang
splenocyt
ospgag
conb
immun
group
cell
ospenv
mn
immun
group
vitro
restimul
ospgag
conb
restimul
ospenv
mn
number
rang
cell
ospgag
conb
immun
group
cell
ospenv
mn
immun
group
background
estim
mean
sfu
standard
deviat
sd
group
given
pb
adjuv
cell
restimul
ospgag
conb
cell
restimul
ospenv
mn
data
indic
five
outbr
mice
two
vaccin
group
gener
specif
cmi
respect
immunogen
next
intracellular
stain
cell
perform
splenocyt
isol
four
group
nmri
mice
restimul
vitro
ospgag
conb
percentag
cell
popul
ospgag
conb
immun
mice
significantli
higher
compar
mice
immun
ospenv
mn
fig
b
p
student
ttest
percentag
cell
individu
mice
two
vaccin
group
rang
ospgag
conb
immun
group
ospenv
mn
immun
group
background
calcul
mean
sd
cell
individu
anim
given
pb
adjuv
percentag
cell
individu
mice
two
vaccin
group
rang
ospgag
conb
immun
group
ospenv
mnimmun
group
background
calcul
data
show
immun
osp
induc
specif
tcell
respons
involv
cell
within
anim
genet
divers
popul
mice
next
test
whether
immun
osp
could
gener
prolif
respons
entir
protein
among
genet
divers
nmri
mice
splenocyt
isol
mice
immun
ospenv
mn
restimul
day
vitro
hiv
mn
hiv
gag
protein
splenocyt
prolifer
restimul
env
gag
stimul
index
versu
p
fig
result
demonstr
immun
osp
gener
specif
prolif
immun
respons
whole
hiv
fig
ospenvspecif
prolif
respons
outbr
nmri
mice
two
group
five
outbr
nmri
mice
immun
ospenv
adjuv
splenocyt
restimul
vitro
env
gag
neg
control
protein
cell
growth
measur
hthymidin
incorpor
indic
statist
signific
student
ttest
test
whether
immun
osp
could
induc
specif
ctl
respons
nativ
viral
protein
mice
differ
mhc
background
balbc
b
mice
immun
ospgag
iiib
splenocyt
restimul
ospgag
iiib
vitro
day
cr
releas
assay
perform
test
ctl
activ
observ
specif
lysi
target
cell
balbc
mice
mice
infect
vaccinia
viru
vv
express
gag
iiib
vvgag
compar
target
cell
infect
wildtyp
vv
fig
b
moreov
effector
cell
balbc
mice
kill
cell
puls
peptid
restrict
epitop
fig
c
howev
effector
cell
immun
lyse
cell
b
fig
find
indic
although
effector
cell
mous
strain
recogn
kill
cell
express
gag
protein
epitop
recogn
effector
cell
differ
recogn
mice
background
next
sought
test
immun
osp
gener
prolif
respons
whole
viral
protein
two
inbr
mous
strain
splenocyt
balbc
mice
immun
ospgag
iiib
isol
restimul
vitro
either
solubl
gag
iiib
protein
ospgag
iiib
prolif
respons
measur
cell
mous
strain
prolifer
respons
stimuli
respons
control
protein
ovalbumin
ova
fig
b
find
confirm
immun
osp
induc
immun
respons
crossreact
nativ
viral
protein
pool
splenocyt
cocultur
target
cell
b
respect
infect
recombin
vaccinia
viru
express
gag
vvgag
wildtyp
vaccinia
viru
vvwt
treat
medium
cocultiv
altern
cell
c
cell
also
puls
peptid
known
balbc
hiv
gag
iiib
ctl
epitop
hiv
clade
c
env
peptid
specif
lysi
measur
cr
releas
next
sought
test
osp
could
gener
cmi
human
cell
differ
mhc
background
ex
vivo
stimul
human
peripher
blood
lymphocyt
pbl
osppuls
dc
two
leukopack
differ
anonym
donor
pbl
separ
cocultur
three
round
vitro
irradi
autolog
dc
puls
without
ospsiv
env
chromium
releas
assay
perform
week
last
stimul
effector
cell
show
higher
lysi
target
cell
autolog
blymphoblastoid
cell
line
blcl
infect
vv
express
sivgagpolenv
vvsivgp
compar
blcl
infect
wildtyp
vv
fig
b
determin
lysi
target
cell
mhc
restrict
effector
cell
cocultur
target
cell
chromium
releas
assay
result
show
recognit
kill
fig
b
result
indic
osppuls
autolog
dc
abl
induc
mhcrestrict
proteinspecif
ctl
activ
ex
vivo
pbl
recogn
cell
antigen
protein
degrad
peptid
fragment
contain
epitop
bound
mhc
class
ii
molecul
cell
surfac
earli
studi
shown
intact
viral
protein
detect
cell
surfac
could
recogn
ctl
overcom
enhanc
degrad
antigen
recent
studi
mice
immun
solubl
antigen
hiv
alon
neither
detect
specif
prolif
respons
stimul
whole
protein
elispot
respons
stimul
recombin
envexpress
vaccinia
viru
indic
weak
cellular
immun
respons
induc
solubl
protein
immunogen
vaccin
mice
moder
elispot
respons
seen
specif
stimul
domin
peptid
epitop
bypass
constraint
degrad
effici
intact
exogen
antigen
protein
test
use
osp
vaccin
strategi
present
studi
osp
long
use
assay
vitro
identifi
tcell
epitop
current
proofofconcept
studi
shown
osp
use
broadli
activ
immunogen
immun
osp
gener
specif
tcell
respons
outbr
mice
cell
prolifer
also
respons
restimul
solubl
whole
protein
addit
osp
immun
stimul
specif
ctl
activ
differ
inbr
mous
strain
vaccinia
viru
express
whole
protein
well
immunodomin
epitop
vaccin
anim
also
develop
prolif
respons
osp
well
nativ
protein
lastli
specif
cmi
could
induc
osp
immun
ex
vivo
use
cocultiv
osppuls
dc
autolog
pbl
two
differ
human
donor
thu
osp
immunogen
vaccin
differ
mhc
background
sever
mechan
osp
vaccin
gener
specif
ctl
experi
could
oper
ctl
epitop
usual
consist
peptid
aa
length
peptid
longer
aa
also
function
capac
bind
mhc
class
molecul
directli
contrast
peptid
exceed
epitop
length
shown
enter
cell
undergo
process
proteasom
enzym
bind
mhc
class
molecul
altern
osp
immunogen
experi
may
also
trim
extracellularli
peptidas
follow
direct
bind
mhc
molecul
apc
use
osp
aa
long
probabl
exceed
length
convent
ctl
epitop
base
publish
report
postul
longer
osp
underw
intracellular
extracellular
process
inde
indirect
evid
may
case
ospgag
iiib
immun
balbc
mice
mount
specif
ctl
activ
known
virusspecif
epitop
restrict
sequenc
amqmlketi
ospgag
iiib
includ
two
peptid
contain
sequenc
peptid
ghqaamqmlketin
peptid
amqmlketineeaa
like
least
two
peptid
process
bound
molecul
eventu
stimul
virusspecif
ctl
might
advantag
singl
epitopebas
vaccin
chanc
specif
epitop
osp
present
seem
higher
singl
epitopebas
vaccin
usual
mhc
class
ii
molecul
bind
epitop
aa
length
longer
contrari
mhc
class
molecul
epitop
bind
confin
cleft
mhc
class
ii
molecul
bind
longer
peptid
end
may
protrud
mhc
bind
cleft
howev
peptid
exceed
mhc
class
ii
epitop
length
process
either
cuttrim
first
bind
later
bind
first
cuttrip
later
model
case
osp
aa
long
could
easili
bound
mhc
class
ii
molecul
activ
th
cell
import
maintain
ctl
dc
vaccin
form
puls
autolog
dc
ex
vivo
variou
immunogen
tumor
lysat
rna
peptid
great
potenti
prime
stimul
cell
number
clinic
trial
current
explor
safeti
immunogen
dc
vaccin
shown
addit
element
contain
thelper
epitop
enhanc
efficaci
dcbase
vaccin
osp
contain
epitop
cell
therefor
serv
effect
immunogen
dcbase
vaccin
strategi
test
ex
vivo
data
show
osppuls
autolog
human
dc
could
prime
ctl
activ
viral
protein
ex
vivo
pbl
immunogen
experi
succeed
cell
differ
hla
background
thu
provid
proofofconcept
data
ex
vivo
immunogen
strategi
may
eventu
develop
futur
one
potenti
advantag
osp
vaccin
high
number
epitop
includ
theori
osp
immunogen
includ
possibl
epitop
correspond
fulllength
protein
includ
epitop
cell
inde
result
shown
osp
vaccin
induc
tcell
respons
outbr
mice
trial
advantag
osp
vaccin
promiscu
contain
peptid
sequenc
correspond
protein
includ
epitop
differ
mhc
allel
consequ
vaccin
broad
immunogen
vaccin
recipi
divers
genet
background
result
outbr
differ
strain
inbr
mice
shown
similar
epitopebas
vaccin
osp
immunogen
contain
viral
element
case
cancer
vaccin
oncogen
element
gener
nonrel
immun
eg
immun
vector
avoid
fact
gener
specif
cellular
immun
novel
cellular
oncogen
mice
use
osp
vaccin
approach
pilot
experi
vaccin
mice
statist
signific
delay
tumor
growth
compar
control
mirshahidi
et
al
unpublish
data
furthermor
osp
expect
pose
safeti
risk
contrast
concern
might
aris
live
vaccin
vector
thu
preclin
clinic
evalu
conduct
singl
mixtur
osp
given
clinic
indic
osp
vaccin
also
advantag
peptid
vaccin
made
larg
quantiti
stabl
easili
transport
howev
lower
product
cost
osp
vaccin
remain
challeng
futur
summari
demonstr
use
osp
overcom
need
identifi
individu
epitop
match
mhc
type
moreov
osp
gener
ctl
th
respons
broad
popul
vaccin
recipi
thu
osp
vaccin
hold
promis
novel
cmibas
vaccin
strategi
viral
infect
possibl
also
malign
